98-17212. Antiviral Drugs Advisory Committee; Notice of Meeting  

  • [Federal Register Volume 63, Number 124 (Monday, June 29, 1998)]
    [Notices]
    [Page 35238]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 98-17212]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    
    
    Antiviral Drugs Advisory Committee; Notice of Meeting
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Notice.
    
    -----------------------------------------------------------------------
    
        This notice announces a forthcoming meeting of a public advisory 
    committee of the Food and Drug Administration (FDA). At least one 
    portion of the meeting will be closed to the public.
        Name of Committee: Antiviral Drugs Advisory Committee.
        General Function of the Committee: To provide advice and 
    recommendations to the agency on FDA's regulatory issues.
        Date and Time: The meeting will be held on July 14 and 15, 1998, 
    from 8:30 a.m. to 5 p.m.
        Location: Bethesda Holiday Inn, Versailles Ballrooms I and II, 8120 
    Wisconsin Ave., Bethesda, MD.
        Contact Person: Rhonda W. Stover, or John B. Schupp, Center for 
    Drug Evaluation and Research (HFD-21), Food and Drug Administration, 
    5600 Fishers Lane, Rockville, MD 20857, 301-827-7001, or FDA Advisory 
    Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
    Washington, DC area), code 12531. Please call the Information Line for 
    up-to-date information on this meeting.
        Agenda: On July 14, 1998, the committee will hear presentations 
    concerning general regulatory issues from the Division of Antiviral 
    Drug Products.
        Procedure: On July 14, 1998, from 8:30 a.m. to 1 p.m. the meeting 
    is open to the public. Interested persons may present data, 
    information, or views, orally or in writing, on issues pending before 
    the committee. Written submissions may be made to the contact person by 
    July 6, 1998. Oral presentations from the public will be scheduled 
    between approximately 11 a.m. and 12 m. on July 14, 1998. Time allotted 
    for each presentation may be limited. Those desiring to make formal 
    oral presentations should notify the contact person before July 6, 
    1998, and submit a brief statement of the general nature of the 
    evidence or arguments they wish to present, the names and addresses of 
    proposed participants, and an indication of the approximate time 
    requested to make their presentation.
        Closed Committee Deliberations: On July 14, 1998, from 1 p.m to 5 
    p.m., and on July 15 from 8:30 a.m. to 5 p.m., the meeting will be 
    closed to permit discussion and review of trade secret and/or 
    confidential commercial information (5 U.S.C. 552b(c)(4)). The meeting 
    will discuss information relevant to pending investigational new drug 
    applications and drug development plans.
        Notice of this meeting is given under the Federal Advisory 
    Committee Act (5 U.S.C., app. 2).
        Dated: June 22, 1998.
    Michael A. Friedman,
    Deputy Commissioner for Operations.
    [FR Doc. 98-17212 Filed 6-26-98; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
06/29/1998
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
98-17212
Pages:
35238-35238 (1 pages)
PDF File:
98-17212.pdf